Abstract
Background: Randomized phase 3 trial of cisplatine/pemetrexed (CDDP/PEM) combination chemotherapy for non-small cell lung cancer (NSCLC) comparing with cisplatine/gemcitabine (CDDP/GEM) combination chemotherapy revealed to be non-inferiority for efficacy with less toxicity. Also, in the subgroup analysis for non-squamous cell carcinoma (non-SQ), the CDDP/PEM group was significantly better for response rate and overall survival in comparison to the CDDP/GEM group. Currently, CDDP/PEM combination chemotherapy is one of the standard chemotherapy for advanced non-SQ NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
